Home / Transcripts / Alpha Cognition Inc. (ACOG) · March 26, 2026

Alpha Cognition Inc. (ACOG) Earnings Call Transcript & Summary

March 26, 2026

NASDAQ US Health Care Biotechnology earnings 44 min

What were the key takeaways from Alpha Cognition Inc.'s March 26, 2026 earnings call?

In the fourth quarter and full year fiscal 2025, Alpha Cognition Inc. (ACOG:US) reported total revenues of $2.8 million, driven primarily by net product sales of $2.5 million from ZUNVEYL, the company's oral treatment for Alzheimer's disease. For the full year, total revenue reached $10.2 million. Management highlighted strong demand indicators, including a 62% quarter-over-quarter growth in bottles dispensed and a significant increase in prescriber engagement, which positions the company for continued growth in 2026. However, operating expenses rose sharply to $10.7 million for the quarter, resulting in a net loss of $6.9 million, raising concerns about future profitability despite a solid cash position of $66 million.

What topics did Alpha Cognition Inc. cover?

What were Alpha Cognition Inc.'s March 26, 2026 results?

Alpha Cognition's strong demand growth for ZUNVEYL and expanding payer access are positive signs for future revenue growth. However, rising operating expenses and net losses raise concerns about the path to profitability. Investors should monitor the execution of clinical studies and the effectiveness of new sales strategies as potential catalysts for stock performance in 2026.

Earnings Call Speaker Segments

Henry Du executive
#1

Sherry, thank you. Hello, everyone, and we're glad you could join this Alpha Cognition call about how we did in the fourth quarter and the whole of fiscal 2025. Our financial results came out in a press release issued after the market shut today. Joining me are Michael McFadden, who serves as Alpha Cognition's Chief Executive Officer, and our Chief Operating Officer, Lauren D'Angelo. Today's call is available via the investors section on the company's website, www.alphacognition.com. During this call, management might make certain forward-looking statements concerning future events and how the company will perform going forward. Such forward-looking statements represent Alpha Cognition's present view of existing trends and information. Statements of that forward-looking nature shouldn't be treated as promises about what will happen down the road; they carry risks and uncertainties, among them the ones described in the risk factors portion of the company's most recent SEC filings. What actually comes to pass could end up substantially different from what those statements anticipate. For additional details about forward-looking statements, please look at the note on that subject included in our earnings press release that went out before this call. Keep in mind as well that our actual consolidated financial results are still pending the completion of our annual audit procedures. We expect to report those actual audited consolidated financial results alongside the filing of our annual report, which we anticipate submitting on or around 31st March 2026. What we're reporting today on a consolidated basis could end up looking different once the books are closed, whether because of adjustments that come out of the audit or other things that pop up before the financials are locked down and submitted. Nothing shared during this call is meant to stand in for the audited consolidated statements and the notes that go with them. So please don't lean too heavily on the figures we're going over here — management put them together, and management owns that responsibility. And for anyone catching the replay later, we're holding and recording this call on March 26, 2026. After that point, Alpha Cognition might have issued further statements about the subjects covered here. For the latest information, please check the company's newest press releases along with its active SEC filings. Unless applicable securities regulations demand otherwise, Alpha Cognition accepts no duty to revise these forward-looking statements. At this point, I'll hand things over to Michael.

Michael McFadden executive
#2

Thank you, Henry, and hello everyone this afternoon. We're grateful you've set aside the time to join this call. Three complete quarters have now passed since ZUNVEYL became commercially available for mild to moderate Alzheimer's disease. I want to note for everyone that ZUNVEYL is recognized as the first new oral Alzheimer's therapy to win approval in more than fifteen years, and from our perspective, it holds considerable promise in long-term care, where symptom control, tolerability, and behavior management are central to the choices made about care. Here's a summary of our results, how the commercial launch is progressing, and our 2026 priorities: the fourth quarter and fiscal year were marked by the following. ZUNVEYL kept generating more sales, and demand for it continued to broaden. We also gained further ground in long-term care, where prescribing grew in both reach and intensity across that $2 billion high-volume market. On the payer side, we made headway as well, signing a second agreement with a national PBM, so we are now under contract with two of the four biggest PBMs in the country. During Q3, the company brought in $40 million, giving us room to scale up our commercial efforts and payer engagement work as needed. Just as important, our financial base stayed solid, which we think leaves the company amply funded and on a clear route to operational profitability in 2027. In addition to the strong commercial and operational progress we've made, we shared news about three real-world studies that are starting or will start in 2026; through these studies, we'll generate more evidence to reinforce how ZUNVEYL is positioned with payers, and to give healthcare providers further support when they need a well-tolerated therapy that shows behavioral and cognitive efficacy for their patients. Later, Lauren, our COO, will join and share more detail on the commercial strategy's momentum, and she'll also comment on the payers, who clearly are a key part of how we penetrate the market. Before I get into our leading indicators for demand and adoption, let me touch briefly on revenues. During Q4, our total revenues came in at $2.8 million, which included $2.5 million in net product revenues from ZUNVEYL. From launch through the close of 2025, Alpha Cognition's cumulative revenues reached $10.2 million, and we see this as an important early base for the company. That said, we understand that during the early launch period, reported revenue can be shaped by how quickly payer coverage develops and by the national growth in prescribing patterns, and it might not completely capture the product's long-term potential. That's why we continue to focus on the leading indicators that show us whether ZUNVEYL is establishing a durable, scalable trajectory within the long-term care setting. What we're paying closest attention to right now are the signals of underlying demand and whether adoption will hold up — especially how often patients reorder, growing confidence among providers, and broader payer access. Those, in our view, are the strongest indicators of durable results and growth ahead. Looking at demand signals: during Q4 we dispensed 4,941 bottles of ZUNVEYL, and 1,859 of those came in December by itself — our best month to date. Across the quarter, our sales force reached roughly 2,000 nursing homes, bringing our total since launch to nearly 4,000 distinct facilities. The prescribing depth we're observing is also giving us reason for optimism. Compared with Q3, the number of prescribing physicians rose 50%, and homes with prescriptions on a cumulative basis grew 69% in Q4, an early signal that adoption is widening across our commercial footprint. If we step back, we think the adoption curve is behaving the way we'd anticipate over the long term. Providers begin carefully. They put a small number of patients on treatment; they watch tolerability and the clinical outcomes those patients experience, and after that they progress to broader use. Turning to payers, access remains a significant point of friction when it comes to prescription approvals, yet it is also a significant opportunity for the company. We're working with payers right now, presenting strong evidence that should translate into expanded reimbursement for ZUNVEYL across the next several quarters. Some good news from this quarter: we finalized another national PBM agreement, which follows the initial one we told you about previously. That means two of the four big PBMs that are critical to our long-term care operations are now under contract with us. The next step is downstream pull-through — ensuring that the coverage we've negotiated actually turns into real access at the plan level, ideally with minimal or zero restrictions and a smoother prior authorization experience. We believe progress on that front could serve as a significant catalyst for new patient starts and for durable growth. Lauren's going to walk through that further, covering her timeline for both initial uptake and wider rollout. Regarding how ZUNVEYL is doing clinically, results look steady, and there have been minimal side effects flagged. Among the gastrointestinal issues that do get flagged, the rate stays within the low single digits. When the quarter wrapped up, only a pair of GI events had come in through spontaneous reporting, even though at this point in a launch we'd have expected those reports to number in the hundreds. Turning to medical affairs, the company closed out the year having submitted and presented 15 abstracts and posters at medical meetings and conferences. These figures give us a strong starting point for teaching the market about acetylcholinesterase, which has been a major gap for the past ten years. This year, the medical team is turning its focus to ZUNVEYL data on adverse events, behavioral response, and MOA, or mechanism of action — areas we think distinguish ZUNVEYL from other drugs in its class. Last quarter, the company shared news of three studies: two in long-term care, BEACON and CONVERGE, and one in the outpatient setting called RESOLVE. In our view, the long-term care findings will set us apart with our customers, because so few long-term care studies have ever been finished. The data we're going to share from BEACON will focus on how well ZUNVEYL is tolerated, along with its cognitive and behavioral effectiveness. Enrollment for this study began back in February, and so far we're quite encouraged by both the number of researchers involved and the caliber of their work. Top-line results should reach us in the fourth quarter of 2026. CONVERGE gets underway in April, and because of the way that trial has been structured, we anticipate being able to share top-line findings quickly — during the third quarter of 2026. RESOLVE launches in the second quarter, taking place in an outpatient environment. It's our belief that what emerges from RESOLVE will help the commercial team in its promotional efforts, and at the company level it might open the door to expanding the label. On the R&D side, progress continues on the sublingual formulation, and a comparative PK study against our tablet as well as our intranasal formulations will begin in Q2 of this year. Management believes that a local toxicity study alongside an equivalent PK data set should be enough to move the product forward into the clinic. Turning to business development, CMS Pharma, our partner in Asia, keeps advancing through the regulatory process across multiple countries in Asia. We expect two strategic product approvals during 2026, and those could open incremental long-term growth opportunities for the company. A business development milestone payment is still pending approval, tied to a regulatory approval with the Chinese government. Our expectation is that this payment will come through in 2026, though the precise moment is unclear; in our view, approval itself isn't in doubt — only the timing is. With the Chinese regulatory authorities, we continue to engage constructively throughout this process. Emerging opportunities in the long-term care market remain a focus the company keeps capitalizing on. Foremost among them is ZUNVEYL, optimally positioned with clinically meaningful benefits, cognitively and behaviorally alike, for treating symptoms associated with Alzheimer's. As mentioned, $40 million was raised by the company in Q3, and that capital was put to work right away. We've broadened our field team's reach among long-term care medical directors and the consultant psychiatry community. We also rolled out marketing assets designed to help establish ZUNVEYL as the preferred option for managing Alzheimer's disease symptoms. By adding to our sales team and strengthening our promotional activities, we'll be ready to capture these opportunities during the upcoming quarter. Because of that spending, along with the encouraging early signs of demand we're observing, we're confident the company has sufficient funding to carry out our commercial plan, and we're concentrated on reaching operating profitability by 2027. Lauren will share additional details about our commercialization efforts in a moment, but before that, Henry will walk us through the company's financial results. I'll hand things over to Henry now.

Henry Du executive
#3

Thank you, Michael, and good afternoon to all of you. In going over our results for the fourth quarter and the full year 2025, I'd ask that you follow along with today's press release or our Form 8-K filings. My plan is to start with a look at how we performed financially in the fourth quarter and the full year 2025, then give you an update on the balance sheet and what we expect for 2026. On the whole, the year showed ongoing commercial momentum for ZUNVEYL, backed by more prescribers coming on board and the money we've put into our commercial infrastructure. Let's start with revenue. During the fourth quarter, our total revenue came to $2.8 million, mostly from $2.5 million in net product sales of ZUNVEYL, which is our lead commercial product. On top of that, we recorded $259,000 in licensing revenue tied to our collaboration with CMS Pharma. For the full year, total revenue reached $10.2 million, which included $6.8 million in net product sales of ZUNVEYL. These figures show adoption growing at a steady pace, and prescribers and caregivers keep giving us favorable feedback about how ZUNVEYL is affecting patients. Now for operating expenses. Our total operating expenses in the fourth quarter came to $10.7 million, made up of $258,000 in cost of goods sold and cost of revenues plus $10.4 million in SG&A and R&D expenses. That's against $2.7 million in operating expenses during the fourth quarter of 2024. Across the full year 2025, total operating expenses were $32.9 million, including $1.9 million in cost of goods sold and cost of revenues, versus $12 million in 2024. The rise from one year to the next mainly reflects greater SG&A expenses connected to our growing commercialization organization, such as personnel costs, as we keep building out our sales team and backing the launch and commercialization of ZUNVEYL. Consequently, we posted an operating loss of $7.9 million for the quarter, versus $2.7 million in last year's fourth quarter; for the full year, the operating loss came to $22.7 million, versus $12 million in 2024. Shifting to net loss; in the fourth quarter of 2025, our net loss was $6.9 million, or $0.30 per share, against a net loss of $5.8 million, or $0.52 per share, during the same period a year earlier. For the full year 2025, net loss came to $20.7 million, or $1.17 per share, against $14.8 million, or $2.04 per share, in 2024. Those figures take in a gain from change in fair value of warrant liabilities of $441,000 in the fourth quarter and $88,000 for the full year, which compares with losses of $3.3 million and $3.2 million, respectively, in the same periods a year ago. Shifting to the balance sheet; our financial position remains strong and we still carry no debt. As of December 31, 2025, unrestricted cash and cash equivalents stood at approximately $66 million, which takes in roughly $38 million in net proceeds we raised in October 2025 via our equity offering and overallotment exercise. Given our current operating plan, we think this capital gives us operational runway well into 2027, funding both our commercial initiatives and our ongoing development activities. On the subject of what we anticipate for 2026, consistent with what we've done before, no formal revenue guidance is being offered. That said, we do anticipate ZUNVEYL sales will keep growing sequentially across 2026, driven by rising physician awareness and further expansion of payer access. Last, looking at expenses, our present expectation for operating expenses across full year 2026 is a range of $54 million-$58 million. The main driver of this increase is the planned clinical studies meant to produce additional efficacy data for ZUNVEYL, along with ongoing investment in sales and marketing efforts to further educate prescribers about our drug's benefits. With that, I'll hand the call over to Lauren. Lauren?

Lauren D'Angelo executive
#4

Thank you, Henry. For ZUNVEYL's U.S. rollout in long-term care, the fourth quarter represented what we see as a key turning point. Continued expansion alone isn't what we're witnessing at this point; rather, it's durable adoption that keeps picking up speed. Total demand during Q4, which we measure by bottles dispensed, came to 4,941 bottles, a rise of 62% versus the prior quarter. Equally significant, demand gained strength as the quarter went on, with 1,859 bottles dispensed during December — the best month we've had since launch. That December result provides real momentum heading into 2026. Ex-factory shipments may swing around as wholesalers adjust inventory, but at this point the key measure is underlying patient demand, and that keeps growing steadily, quarter after quarter. Adoption is building on itself. Repeat behavior stands out as the most encouraging indicator we're observing. During Q4 we engaged 1,986 homes, which brings the cumulative number of unique homes reached since launch to 3,856. Orders came from 729 homes, and 82% of those — more than 600 — were reorders. Seeing that degree of repeat ordering so early in the launch shows us ZUNVEYL has moved past initial trial use and is now becoming part of facility treatment protocols; we also gained close to 100 new homes placing orders during the quarter's final month, which shows new adoption keeps happening even while homes already on board increase their usage. Turning to prescribers, we logged 3,681 total HCP calls, among them nearly 2,000 prescriber calls. Roughly 865 prescribers submitted orders in Q4, and 69% — approximately 600 prescribers — were repeat writers. That repeat rate matters enormously. A predictable adoption curve is what we keep seeing. Providers begin carefully. They treat one or two patients. They notice behavioral improvement along with strong tolerability, and prescribing then widens. That expansion phase is where we are now. Acceleration is also being fueled by behavioral differentiation. Our behavioral positioning keeps resonating strongly. Physicians grow more and more at ease titrating patients up to the 10 mg therapeutic dose, and that ease is developing more quickly than we anticipated. It reflects rising confidence in ZUNVEYL's tolerability profile and its limited GI adverse events. In long-term care, behavior shapes resource utilization, caregiver burden, and facility stability. When providers witness meaningful improvement in that area, adoption speeds up, and we hear this consistently across regions. The next catalyst for us is payer unlock. Demand is accelerating, yet payer coverage remains at an early stage of pull-through. As unrestricted coverage widens and prior authorizations become smoother, we anticipate less friction when initiating patients and greater velocity in new starts. Notably, today's demand growth is happening even with limited unrestricted access. Once coverage broadens, we think it will work as a force multiplier. Also, as we mentioned on our previous call, we anticipated signing a second national PBM contract before the end of 2025, and I'm happy to say we hit that milestone. Two of the four major PBMs are now under contract, and our sharp focus is on downstream plan execution. We expect early traction to appear in Q2, with wider implementation in Q3. One more major driver for 2026 is getting peer-to-peer education up and running. Back in January, we finished training a national group of speakers — 48 key opinion leaders spanning long-term care and psychiatry — and those individuals are now set to start running structured educational sessions nationwide. Before this, our field team was responsible for most of the adoption we saw. With peer-to-peer education scaling up, we anticipate stronger physician pull-through, wider clinical validation, and faster growth in prescriber confidence, especially with our later adopters. Within long-term care, hearing from trusted colleagues matters a great deal. Our belief is that this effort will boost awareness, strengthen ZUNVEYL's behavioral differentiation, and fuel ongoing acceleration through 2026. Let me explain what has us so enthusiastic about 2026. Stepping back, what we observe is robust sequential demand acceleration, elevated repeat ordering rates, rising prescriber confidence, more ordering homes coming on board, greater comfort with therapeutic dose titration, broader payer access, the launch of national peer-to-peer education, and real-world data milestones on the horizon. Proving product-market fit is behind us. Scaling it is what we're focused on now. Entering 2026, our priorities are clear: grow penetration per home, strengthen prescriber relationships, speed up payer pull-through, and execute with discipline. Given the trajectory we exited Q4 with, we believe ZUNVEYL is positioned well for continued acceleration. With that, I'll hand things over to Michael.

Michael McFadden executive
#5

Appreciate that, Lauren. Everyone here is committed to carrying out these quality calls alongside high-value medical directors and psychiatry consultants. We are sitting down with health plans so that our PBM contracts get pulled through, and we're putting effort into handling the reimbursement procedure efficiently with the customers we serve. Our partnership with CMS Pharma keeps expanding. Together with our partner, we're navigating the regulatory pathway to secure approvals for ZUNVEYL across two countries during this year; over the past quarter, more than 40 prescribers have been visited by our leadership team. The clinical outcomes they observe with ZUNVEYL are strong. The tolerability they witness in patients is quite favorable. They notice gains in cognition along with betterment or full elimination of behaviors, and they frequently share that with us throughout these meetings. This makes us confident that once we lower the friction points with payers, our demand will increase. Even more crucially, we think the company has sufficient funding to execute, and our attention is on pushing toward operational profitability in 2027 while establishing a lasting commercial franchise centered on ZUNVEYL. At this point we'll open it up for questions. Operator?

Ram Selvaraju analyst
#6

I really appreciate you fielding our questions, and congrats on everything you've accomplished lately. To kick things off, I'd like to focus on a few commercial points. Could you share any extra detail on when you expect the remaining payers to convert — the ones you haven't converted yet — and also when you think you might begin promoting to neurologist prescribers, as opposed to long-term care facilities and those specialist prescribers?

Lauren D'Angelo executive
#7

Of course. Ram Selvaraju, thank you for asking. Let's begin with payer conversion timing. As all of you have heard from us, we're quite thrilled to have signed two of the big four, which accounts for a meaningful share of our total business. Looking at those two PBMs, on one of them we currently sit at roughly 16% open business. We continue to work extremely hard to pull through the remaining regional plans under that PBM; that second PBM was just signed at the close of last year. At this point we're working through the downstream accounts. The largest downstream accounts are truly the ones we're going after. We're having excellent discussions with those regional payers. As for when adoption will begin among those regional plans, our expectation is that we'll see some acceleration in Q2 — a modest number of those plans will probably bring us on in Q2 — and broad implementation in Q3 is when we anticipate a substantial pickup from the downstreams. Turning to promotion in the neurologist or specialty space, our approach has always been that once we approach break even — profitability in 2027 — that's the point at which we'd seek to expand into neurology.

Ram Selvaraju analyst
#8

All right, and moving to the clinical development side, I'd like to focus closely on a couple of those efforts, and one is clearly the ongoing clinical program for ZUNVEYL. Specifically, I was hoping you might share a bit more detail on the main — or what you'd consider the main aspirational messages, so to speak — coming out of the CONVERGE study, especially where polypharmacy is concerned. Obviously that trial is going to yield a great deal of valuable information, but we were just trying to gauge, assuming you obtain what you anticipate from this study, how that feeds into your longer-term promotional approach for ZUNVEYL, and how much of a pivot point this study might become among prescribers?

Michael McFadden executive
#9

Excellent question. CONVERGE is an analysis of data from the long-term care sector, and our intention is to assess polypharmacy along three dimensions. Within long-term care for the Alzheimer's population, multiple-medication use is extremely widespread among patients who have trouble sleeping that arises alongside the other drugs in this class. Patients experiencing gastrointestinal issues, which show up very frequently with other drugs in this class. For managing behaviors that other drugs in this class either barely help with or cannot help control at all. Based on what we've observed in these facilities, we expect that once ZUNVEYL is adopted and used, we'll witness a decline in that multiple-medication use, though the data will reveal what actually happens, and that will be among the top priorities this study examines; it will additionally examine areas such as adherence, tolerability, dosing, and consistency when comparing ZUNVEYL against other drugs in this class. A wealth of data across all those areas will be available to us. We believe that will prove truly essential for providers as well as for decision-makers when it comes to establishing how ZUNVEYL should be positioned with health plans and figuring out the way they wish to deploy ZUNVEYL across the long-term care marketplace.

Ram Selvaraju analyst
#10

All right, excellent. And then finally, regarding the sublingual formulation that's still preclinical, I have three brief questions. First off, I'd like to hear whether you can offer any further detail about how precisely you anticipate getting this into the clinic during 2026, and what steps would need to come first before that milestone could be achieved. My second question: could you perhaps lay out for us your expectations around what the clinical development timeline and approach would be for this sublingual version? My assumption is that it would likewise be covered by the 505(b)(2) route, though maybe you can provide a bit more insight into how you see it progressing toward a possible commercial launch. Naturally, it would help if you could share some idea of when it could hit the market. And should you have any early thinking, presuming clinical development succeeds, about how this sublingual version would fit alongside ZUNVEYL and how it could extend your footprint across the Alzheimer's community overall. Also, whether any technical plans are being considered around testing the feasibility of creating formulations that are not just sublingual ZUNVEYL but could also potentially yield combination therapies — meaning essentially delivering both benzylamine and possibly other anti-Alzheimer's drugs together in one sublingual product. Thanks very much.

Michael McFadden executive
#11

There's quite a bit to address there. I'll begin with where this sits in the market when it comes to the sublingual. What's driving our investigation and our effort to push the sublingual forward? Within long-term care, estimates suggest as many as 20% of patients suffer from dysphagia or aphasia — meaning they cannot swallow, or struggle to swallow, a tablet or capsule form of any drug. Right now, Alzheimer's patients facing this problem either rely on a patch, or, when a capsule or tablet is involved, it gets crushed or opened and placed into a feeding tube or blended with applesauce before being given to the patient. As you might expect, that is quite demanding and hard to manage. With the sublingual, our belief is that it will replace a patch that is extremely awkward to use and replace a very troublesome method of giving it in applesauce or through a tube, simply by placing it beneath the tongue, where it dissolves in seconds; administration becomes easy, assuming the data supports our ability to proceed with this compound. Now let me turn to what we're examining and the milestones we must accomplish and get past in order to bring this into the clinic. To begin, we will launch a PK comparative study pitting our sublingual against our tablet and our intranasal formulation. Should that PK data demonstrate parity, we'll rely on it as the foundation for entering the clinic together with FDA. From there, we'll need to finish a Type C meeting, which should take place in the late summer with FDA, and following a favorable Type C meeting, we would move the sublingual formulation into the clinic, probably in the earliest portion of 2027. All of this hinges on what the agency's data shows, but our view is that nothing beyond this is required. All remaining data that we think is necessary for taking the product into the clinic has now been finished. Should we make it into the clinic, a modified 505(b)(2) pathway is what we'd pursue. As we currently see it, a 505(b)(2) study would be finished, and after that a tolerability study using the sublingual would follow, which could be label-enabling for that asset, letting us use that data both for promotion and in the label for the sublingual. How long such a study has to run is still to be determined. That will form part of our Type C meeting discussion with FDA. Advancing our program for cognitive impairment with mild traumatic brain injury via the sublingual formulation is also something we plan. For that patient population, it's an easy-to-take formulation that would be simple to administer; we have dual use for that asset, and dual programs are what we will utilize the asset for.

Ram Selvaraju analyst
#12

Okay.

Michael McFadden executive
#13

Regarding con-

Ram Selvaraju analyst
#14

Just one quick clarification.

Michael McFadden executive
#15

Yeah.

Ram Selvaraju analyst
#16

My apologies — please continue.

Michael McFadden executive
#17

As for combination therapy, it will come after both of those programs; at present, those two programs hold the first and second spots in the company's priorities for medical development.

Ram Selvaraju analyst
#18

Alright, only a single commercial point I want to clear up. My understanding is this — assuming the sublingual version makes it to market, and the specific purpose there is handling dysphagia or aphasia among Alzheimer's patients, you'd expect to be able to use the sales and marketing operation you already have in place, and at that point you wouldn't require bringing in extra sales firepower. Does that assumption hold up?

Michael McFadden executive
#19

That's right, you've got it. The sublingual and the sales infrastructure we already run have 100% synergy between them.

Ram Selvaraju analyst
#20

Thank you.

Dave Storms analyst
#21

Good evening, and thanks for fielding my questions. I wanted to pick up where we left off regarding the growth of the sales rep team. What's the current picture? Has that effort wrapped up, or are there regions still needing coverage? And as a related point, once the sales organization keeps scaling, at what point might we see an inflection, if one comes at all? I'm just trying to get a sense of how long it takes new reps to ramp up and so on.

Lauren D'Angelo executive
#22

Of course. Thanks for asking, Dave. During the last quarter, the team stayed focused on growing the sales force so that we could achieve broader reach and greater frequency across our customer base. I'm happy to report that every one of those added positions has now been filled. You asked how many territories remain open for us to fill. We acted very fast. That's what comes from having a long-tenured leadership group in long-term care. I believe we've discussed this often on earlier calls; we managed to grow our sales force beginning in January. At that point, we were essentially at 98% filled, and more recently we brought on a few additional reps during March, which finished off our entire sales force expansion; that stands as a single crucial lever we expect will speed up the business considerably. Beyond that, there are a few other steps we've taken alongside this sales force. We've sharpened our focus on behaviors and gone further into psychiatry. That served as a major reason, or driver, behind our decision to grow the sales force, since we discovered that for our drug, the responses we receive concerning behavioral symptoms exceed what we had anticipated, and we recognized the need to broaden our reach to the psychiatry customer inside long-term care. We've accomplished that; we're deploying these new reps, these expanded reps, to carry that message. In addition to that sales force, since we recognize payer represents a point of friction for us, we've grown our reimbursement team; this means that as the team grew and we placed more sales reps in the field, we now also have a larger field reimbursement team capable of helping pull that demand through from the payer side. That has served as another crucial lever for us. Naturally, alongside the larger sales force — I realize your question concerned the sales force — there's a ripple effect across all the other levers we implemented to fully back that expansion, namely the training of the 48 thought leaders, so that with the added sales force, they can tap into the KOLs and get out there supporting peer-to-peer education; we genuinely believe those four essential areas are the levers that will help us speed things up. And when that happens, we expect it to matter a great deal.

Dave Storms analyst
#23

That's fantastic, Lauren D'Angelo, and thank you for that. Could I perhaps return to one point you brought up in your response regarding growing our base of psychiatry clients? Since ZUNVEYL has now launched and you're beginning to see how the market responds, how would you say that marketing effort is shifting in other ways? And-

Lauren D'Angelo executive
#24

Of course.

Dave Storms analyst
#25

Okay, sure — please, go ahead. Thanks.

Lauren D'Angelo executive
#26

Of course. So, at the time we first brought that product to market — and honestly, for a number of years before it even launched, while we were working out how ZUNVEYL should be positioned — tolerability was the central focus for us. Specifically, the absence of gastrointestinal side effects. It's well known that GI problems are a major concern associated with acetylcholinesterase inhibitors, so that became the area we really emphasized. And then, when we did launch, we also highlighted the dual mechanism of action, since that's what sets us apart from the other acetylcholinesterase inhibitors in the class. So those two things formed the foundation of how we positioned ZUNVEYL at launch. Okay, real quick — and I believe you all recall from the past few calls — what we kept hearing from customers about the way this drug affected behaviors was simply staggering. What we came to understand is that behaviors are truly the thing that pushes adoption in the nursing home, since behaviors are obviously what doctors worry about most, right, when you have this frail population residing in a nursing home. Our positioning has changed. We continue to emphasize strong tolerability. I mean, as of today, we still have only, you know, two spontaneous reports of GI; we've been on the market for close to a year now. I mean, if you stop and think about it, that's pretty amazing. It's not that it isn't occurring elsewhere—we simply haven't gotten word of it. Our focus has moved considerably toward messaging around behavior. That behavioral messaging is backed by the dual mechanism of action, and it has broadened our prescriber base, since the psychiatrists in a nursing home setting are the ones managing those behaviors. I'd say we still position on GI intolerability, but behaviors and tolerability are truly the two key elements. That's the modest change, though we completed it rather fast, about a couple of quarters back, because we continued to hear excellent accounts from physicians. Dave, here's what I can tell you: from the very first call we had, that initial month after launch, and the accounts we started hearing, those same kinds of accounts come to us regularly. Just yesterday I spoke with a customer, and this is likely the best outcome we've seen so far — a patient who had been residing in a nursing home, displaying awful behaviors, extremely agitated, and yes, there are many patients like this, but this one was hurling objects at the staff. After three months on ZUNVEYL, that patient is heading home. There's simply no better success story out there. We're putting real emphasis on those providers who've given it a try. They adore it. That's visible in the reorders, the recurring purchases. We're drawing on what we've learned. Now we're spreading that know-how through peer-to-peer teaching, so prescribers who haven't yet brought this drug on board can hear those accounts firsthand. And of course, we're zeroing in on how the product performs — specifically its impact on behavior and how well patients tolerate it. I hope that addresses what you asked.

Dave Storms analyst
#27

That really helps a lot. I realize this is just one person's experience, but it makes for a fantastic story. If I could squeeze in one more, Michael, since I truly value what you said about the CONVERGE study — could I ask you to apply that same kind of framing to the BEACON trial? Perhaps you could share any thoughts on what an ideal or aspirational picture for BEACON might look like, and maybe set it side by side with CONVERGE.

Michael McFadden executive
#28

BEACON is a distinct study, since it's going to examine ZUNVEYL tolerability, ZUNVEYL efficacy when it comes to treating cognition, and ZUNVEYL efficacy when it comes to treating behavioral symptomatology. Once that study wraps up, our aspiration is that it shows strong cognitive effects, strong improvement or amelioration of behavioral symptomatology, plus excellent tolerability for ZUNVEYL. That's what we'd hope for. We'll find out what the data says. This study matters a great deal to us, because within the long-term care market — or the long-term care segment of the Alzheimer's market — completed studies are quite scarce. Observational phase IV work is very limited, and phase III studies assessing drug tolerability are nearly nonexistent. This is going to be among the first studies delivering a really solid data set covering 200 patients in the nursing home market. Our plan is to use those data not just with our providers, the physicians doing the treating, but also with the nursing homes that administer care to patients, and equally important, the payers who make coverage decisions on ZUNVEYL's behalf; we believe that study will carry a lot of significance for the company.

Dave Storms analyst
#29

Excellent, thanks. I just want to clear up one thing. Earlier in what you said, you noted that those results should be anticipated during this year's Q4.

Michael McFadden executive
#30

Correct. For BEACON, that's Q4 of 2026, while for CONVERGE, top-line data will come in Q3 of 2026.

Dave Storms analyst
#31

That sounds great. Something we can anticipate. Wonderful. I appreciate you answering my questions, and best of luck during the upcoming quarter.

Michael McFadden executive
#32

Thanks, Dave.

Michael McFadden executive
#33

All right, thank you all for joining today's call. I believe our priorities for 2026 have been made clear to you. Let me restate them: we intend to keep our emphasis on execution in sales. Our attention will also go toward payer coverage, and toward enhancing ZUNVEYL's coverage among our payers. At the same time, we'll put in diligent effort to finish our studies punctually and at a high standard, while pushing our R&D pipeline forward. Beyond those items, just as we've been doing so far, we will keep our costs in check as we steer toward operating profitability in 2027. Expect to receive updates on each of these matters as you track the company across 2026. Thank you for being here.

Operator operator
#34

Thanks. That brings today’s call to a close. At this point, you’re free to hang up, and we appreciate your joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Alpha Cognition Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Alpha Cognition Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.